RecruitingNCT04661215
Pyloric Sphincter Abnormalities in Patients With Gastroparesis Symptoms
Studying Idiopathic gastroparesis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
- Principal Investigator
- Pankaj Pasricha, MDMayo Clinic
- Enrollment
- 150 target
- Eligibility
- 18-85 years · All sexes
- Timeline
- 2026 – 2027
Study locations (6)
- Mayo Clinic Arizona, Scottsdale, Arizona, United States
- University of Louisville, Louisville, Kentucky, United States
- Massachusetts General, Boston, Massachusetts, United States
- Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
- Temple University, Philadelphia, Pennsylvania, United States
- Texas Tech University Health Science Center (TTUHSC), El Paso, Texas, United States
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Massachusetts General Hospital · Temple University · University of Louisville · Wake Forest University · Texas Tech University Health Sciences Center, El Paso · Mayo Clinic
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04661215 on ClinicalTrials.govOther trials for Idiopathic gastroparesis
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT06899217A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.CinDome Pharma, Inc.
- RECRUITINGNCT05981300GpCRC Pediatric Gastroparesis Registry 2Johns Hopkins Bloomberg School of Public Health
- ENROLLING BY INVITATIONNCT06581120GLP_1 RA Ultrasound StudyChildren's Hospital Medical Center, Cincinnati
- RECRUITINGPHASE3NCT06836557Open Label Safety Study of Tradipitant in Idiopathic and Diabetic GastroparesisVanda Pharmaceuticals
- RECRUITINGPHASE2NCT05621811Different Doses of Naronapride Vs. Placebo in GastroparesisDr. Falk Pharma GmbH
- ENROLLING BY INVITATIONNCT05812339Body Surface Gastric Mapping to Evaluate Patients With Upper Gastrointestinal Symptoms and ControlsUniversity of Calgary
- ACTIVE NOT RECRUITINGNCT03626350Prospective Evaluation of the Efficacy and Safety of Submucosal EndoscopyUniversity of Colorado, Denver
- RECRUITINGNCT02165059GI Neuromuscular Pathology Prospective RegistryIndiana University